# A PET Study of the Effects of p38 MAP Kinase Inhibitor, VX-745, on Amyloid Plaque Load in Alzheimer's Disease (AD)

> **NCT02423122** · PHASE2 · COMPLETED · sponsor: **EIP Pharma Inc** · enrollment: 16 (actual)

## Conditions studied

- Alzheimer's Disease
- Mild Cognitive Impairment

## Interventions

- **DRUG:** VX-745

## Key facts

- **NCT ID:** NCT02423122
- **Lead sponsor:** EIP Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04
- **Primary completion:** 2016-07
- **Final completion:** 2016-09
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2019-06-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02423122

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02423122, "A PET Study of the Effects of p38 MAP Kinase Inhibitor, VX-745, on Amyloid Plaque Load in Alzheimer's Disease (AD)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02423122. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*